Radius Health (NASDAQ: RDUS) reported Q1 EPS of ($0.94), $0.20 worse than the analyst estimate of ($0.74).

As of March 31, 2016, Radius had $439.8 million in cash, cash equivalents and marketable securities. Based upon Radius’ cash, cash equivalents and marketable securities balance, Radius believes that, prior to the consideration of revenue from the potential future sales of any of its investigational products, it has sufficient capital to fund its development plans, U.S. commercial scale-up and other operational activities into 2018.

For earnings history and earnings-related data on Radius Health (RDUS) click here.